ID1 and plasma cell myeloma: They found that tumor lysate-pulsed DCs vaccines were more efficient in protecting mice against developing myeloma, delaying the progression of tumor, and inducing tumor regression against established tumor, suggesting a more pronounced advantage of myeloma cells themselves as a source of tumor antigens over Id proteins (103).